Fresenius Medical Care Logo
DE0005785802
578580
FME.DE

Fresenius Medical Care

Loading quotes...

Forecast

Buy
  7
Hold
  9
Sell
  0

  • Fresenius Medical Care falls after US reform plans for dialysis treatment

    Shares of Fresenius Medical Care fell again, at times by more than four percent, after the US Department of Health and Human Services presented reform plans for kidney treatment. Experts warn of increased competitive pressure on the dominant dialysis providers (FMC and DaVita together hold a 74% market share) and possible long‑term declines in dialysis patient numbers. DZ Bank cut its fair value from €54 to €46 but kept its buy rating, while analysts see higher risks but also some preparatory measures by FMC. » More on deraktionaer.de


  • Bernstein Research keeps Fresenius Medical Care at Market-Perform after leadership change, price target €44.65

    Bernstein Research keeps its rating for Fresenius Medical Care at Market-Perform and confirms a price target of €44.65 despite the announced change in group leadership. Analyst Susannah Ludwig expects no change to the 2026 forecast and sees the stronger growth orientation as positive, but warns of an increasingly difficult end market for dialysis. The stock fell 1.9 percent in XETRA trading to €36.72, about 21.6 percent below the price target; year-to-date it has lost 6.3 percent. » More on finanzen.net


  • Fresenius Medical Care replaces CEO Helen Giza with Shervin Korangy, shares under pressure

    Fresenius Medical Care unexpectedly dismisses CEO Helen Giza; her successor will be Shervin Korangy as of Oct. 12. Shares fell sharply after the announcement, as investors were surprised by the personnel move and its timing. The supervisory board criticized a lack of vision and strategy under Giza, while the company will focus more on revenue growth and reinvestment rather than pure cost discipline. Korangy brings international management and pharmaceutical-industry experience and is to shape the next phase of growth. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Fresenius Medical Care has already paid €1.49 in dividends. The last payout was in May.

Financials

In the last quarter, Fresenius Medical Care had revenue of €4.85B and net profit of €217.67M
(EUR) June 2026
YoY
Revenue 4.85B 1.29%
Gross profit 1.31B 7.71%
Net profit 217.67M 3.37%
EBITDA 843.66M 2.59%

Fundamentals

Metric Value
Market capitalization
€10.45B
Number of shares
266.11M
52-week high/low
€50.40 - €36.57
Dividend yield
3.65%
Dividends TTM
€1.49
Beta
0.71
P/E ratio
12.19
PEG ratio
0.26
P/B ratio
0.86
P/S ratio
0.55

Company profile

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Name
Fresenius Medical Care
CEO
Helen Giza
Headquarters Bad Homburg, he
Germany
Website
Sector
Health Care
Industry
Health Care Technology
IPO
07/22/1998
Employees 111,024

Ticker symbols

Exchange Symbol
XETRA
FME.DE
Pnk
FMCQF
SIX
FME.SW
Frankfurt
FME.F
Düsseldorf
FME.DU
Hamburg
FME.HM
Milan
1FME.MI
London
0H9X.L
München
FME.MU
Wien
FME.VI
🍪

Parqet  uses cookies. Learn more